82326-55-4

Usage

Structure

A heterocyclic compound containing a benzene ring fused to an imidazole ring with chlorine atoms attached to the 4th and 6th positions.

Usage

Primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals.

Importance

An important building block in organic synthesis with potential use in the production of various useful compounds.

Chemical properties

The presence of chlorine atoms may impart specific chemical properties, making it suitable for certain chemical reactions and applications.

Upstream product

• 2683-43-4 2,4-dichloro-6-nitroaniline 
• 5233-04-5 3,5-dichloro-1,2-phenylenediamine 
• 149-73-5 trimethyl orthoformate 
• 64-18-6 formic acid 
• 122584-83-2 3,5-dichloro-2-nitroaniline 

Downstream Products

• 846048-99-5 4'-[(4,6-dichloro-1H-benzoimidazol-2-yl)-piperidin-4-ylidene-methyl]-biphenyl-3-carbonitrile 
• 846049-69-2 4-[(4-bromo-phenyl)-(4,6-dichloro-1H-benzoimidazol-2-yl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-65-8 2-[(4-bromo-phenyl)-piperidin-4-ylidene-methyl]-4,6-dichloro-1H-benzoimidazole 

Relevant academic research and scientific papers

BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS

The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists

Biaryl urea lead compound 1 was discovered earlier in our MCH antagonist program. Novel benzimidazole analogues with increased chemical stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model.

Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions

A high yielding one-pot procedure for the generation of 2-substituted benzimidazoles directly from 2-nitroanilines by in situ reduction and cyclization using a microwave procedure is described.